These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34176716)

  • 1. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
    Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T
    J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19.
    Iwata S; Kobayashi O; Kurashima K; Doi Y; Kunishima H; Shinkai M; Tsushima K; Yamato M; Kano A; Hibino M; Yamatake T; Sakurai T; Ogura T
    J Infect Chemother; 2024 Mar; 30(3):219-227. PubMed ID: 37832822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
    Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
    Tsuboi H; Kasamatsu Y; Matsubara S; Sasao A; Kunimitsu K; Munakata N; Ito T; Tsuchido Y; Yamawaki M; Fujita N
    J Infect Chemother; 2021 Jul; 27(7):1072-1075. PubMed ID: 33814353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
    Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
    Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
    Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna ; Kighoma PM; Koundouno FR; Réné Lolamou ; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D;
    PLoS Med; 2016 Mar; 13(3):e1001967. PubMed ID: 26930627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
    Aktaş A; Tüzün B; Aslan R; Sayin K; Ataseven H
    J Biomol Struct Dyn; 2021 Nov; 39(18):7263-7273. PubMed ID: 32783586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.
    Fujii S; Ibe Y; Ishigo T; Inamura H; Kunimoto Y; Fujiya Y; Kuronuma K; Nakata H; Fukudo M; Takahashi S
    J Infect Chemother; 2021 Jul; 27(7):1051-1057. PubMed ID: 33902990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
    Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
    J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir use for SARS CoV-2 infection.
    Boretti A
    Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.
    Padhi AK; Dandapat J; Saudagar P; Uversky VN; Tripathi T
    FEBS Lett; 2021 Sep; 595(18):2366-2382. PubMed ID: 34409597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study.
    Itoh K; Sakamaki I; Hirota T; Iwasaki H
    J Infect Chemother; 2022 Jan; 28(1):124-127. PubMed ID: 34627706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
    Alamer A; Alrashed AA; Alfaifi M; Alosaimi B; AlHassar F; Almutairi M; Howaidi J; Almutairi W; Mohzari Y; Sulaiman T; Al-Jedai A; Alajami HN; Alkharji F; Alsaeed A; Alali AH; Baredhwan AA; Abraham I; Almulhim AS
    Curr Med Res Opin; 2021 Jul; 37(7):1085-1097. PubMed ID: 33890544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
    Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
    Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
    Pertinez H; Rajoli RKR; Khoo SH; Owen A
    J Antimicrob Chemother; 2021 Jul; 76(8):2121-2128. PubMed ID: 34075418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.